Guselkumab in moderate-severe psoriasis: effectiveness assessment

• At: Seville (Spain) (2022)
• Type: Poster
• Poster code: HPS-093
• By: ARAGóN GRACIA, Irene (Hospital Universitario Marqués de Valdecilla, Spain)
• Co-author(s): Mrs Irene Aragón Gracia, Hospital Pharmacist (Hospital Universitario Marqués de Valdecilla, Santander, Spain)
  Ms Lorenzo Perez-Periañez Orrillo, Hospital Pharmacist
  Mrs Julia Sanchez Gundin, Hospital Pharmacist
  Dr Susana Armesto Alonso, Dermatology
  Mrs Clara Fernandez Martinez, Hospital Pharmacist
  Mrs Rosana Lucia Rey Montalban, Hospital Pharmacist
  Mrs Marta Valero Dominguez, Hospital Pharmacist
  
• Abstract:

  Background
  Guselkumab is a human IgG1λ monoclonal antibody that binds selectively to the IL-23, a regulatory cytokine, affects the differentiation, expansion, and survival of T cell subsets and innate immune cell subsets, which represent sources of effector cytokines.
  
  Objectives:
  To evaluate the effectiveness of guselkumab at week 12 in a cohort..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login